3 results
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
The primary objective is to establish the non-inferiority of treating a symptomatic urinary tract infection in patients with a long-term indwelling catheter for 5 days, as compared to the standard duration of 10 days of therapy. Secondary objectives…
Primary objective1. To evaluate efficacy of ILT-101 for the preservation of residual pancreatic β cells function2. To select the optimal regimen of administration of ILT-101.Secondary objectivesTo assess:1. Tregs expansion after an induction period…